BBIOBridgeBio Pharma Inc
BBIO
BridgeBio Pharma Inc5,381
Mkt Cap
$14.88BVolume
2.04M52W High
$84.9452W Low
$31.77PE Ratio
-20.28BBIO Fundamentals
Price
$76.75Prev Close
$77.51Open
$79.6050D MA
$71.07Beta
1.31Avg. Volume
2.08MEPS (Annual)
-$3.79P/B
-7.16Rev/Employee
$598,421.93$16,800.66
BridgeBio Pharma (NASDAQ:BBIO) CEO Sells $2,984,800.00 in Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the business's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $74.62, for a total transaction of $2,984,800.00. Following the completion of the...
MarketBeat·6d ago
BridgeBio Pharma (NASDAQ:BBIO) Raised to "Moderate Buy" at Royal Bank Of Canada
Royal Bank Of Canada raised shares of BridgeBio Pharma to a "moderate buy" rating in a research report on Wednesday...
MarketBeat·9d ago
BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated by Analysts at Royal Bank Of Canada
Royal Bank Of Canada initiated coverage on BridgeBio Pharma in a report on Thursday. They issued an "outperform" rating and a $100.00 price target on the stock...
MarketBeat·10d ago
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on March 18th. The trade occurr...
MarketBeat·10d ago
Allspring Global Investments Holdings LLC Has $77.78 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO
Allspring Global Investments Holdings LLC lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 14,211.5% during the 4th quarter, according to its most recent 13F filing with the...
MarketBeat·18d ago
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twenty-four research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and twenty-three have i...
MarketBeat·18d ago
Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO
Assenagon Asset Management S.A. trimmed its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 87.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 33,513 shares of the company's stock after se...
MarketBeat·19d ago
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.
Zacks·1mo ago
Mizuho Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock
Mizuho upped their price objective on BridgeBio Pharma from $91.00 to $106.00 and gave the company an "outperform" rating in a research report on Wednesday...
MarketBeat·1mo ago
Fred Alger Management LLC Has $10.25 Million Stake in BridgeBio Pharma, Inc. $BBIO
Fred Alger Management LLC boosted its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 729.3% during the 3rd quarter, according to the company in its most recent filing...
MarketBeat·1mo ago
<
1
2
...
>